-
Je něco špatně v tomto záznamu ?
Phototherapy Restores Deficient Type I IFN Production and Enhances Antitumor Responses in Mycosis Fungoides
Z. Yu, P. Vieyra-Garcia, T. Benezeder, JD. Crouch, IR. Kim, JT. O'Malley, PM. Devlin, A. Gehad, Q. Zhan, JE. Gudjonsson, MK. Sarkar, JM. Kahlenberg, N. Gerard, JE. Teague, TS. Kupper, NR. LeBoeuf, C. Larocca, M. Tawa, B. Pomahac, SG. Talbot, DP....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
Grantová podpora
P30 AR069625
NIAMS NIH HHS - United States
T32 AR007098
NIAMS NIH HHS - United States
P30 AR075043
NIAMS NIH HHS - United States
R01 AR065807
NIAMS NIH HHS - United States
U01 CA253190
NCI NIH HHS - United States
R01 CA203721
NCI NIH HHS - United States
R01 AR074797
NIAMS NIH HHS - United States
NLK
Free Medical Journals
od 1938 do Před 1 rokem
Freely Accessible Science Journals
od 1938 do Před 1 rokem
Open Access Digital Library
od 1938-01-01
- MeSH
- CD8-pozitivní T-lymfocyty patologie MeSH
- exprese genu MeSH
- fototerapie MeSH
- furokumariny * terapeutické užití MeSH
- lidé MeSH
- mycosis fungoides * terapie farmakoterapie MeSH
- nádory kůže * terapie farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Transcriptional profiling demonstrated markedly reduced type I IFN gene expression in untreated mycosis fungoides (MF) skin lesions compared with that in healthy skin. Type I IFN expression in MF correlated with antigen-presenting cell-associated IRF5 before psoralen plus UVA therapy and epithelial ULBP2 after therapy, suggesting an enhancement of epithelial type I IFN. Immunostains confirmed reduced baseline type I IFN production in MF and increased levels after psoralen plus UVA treatment in responding patients. Effective tumor clearance was associated with increased type I IFN expression, enhanced recruitment of CD8+ T cells into skin lesions, and expression of genes associated with antigen-specific T-cell activation. IFNk, a keratinocyte-derived inducer of type I IFNs, was increased by psoralen plus UVA therapy and expression correlated with upregulation of other type I IFNs. In vitro, deletion of keratinocyte IFNk decreased baseline and UVA-induced expression of type I IFN and IFN response genes. In summary, we find a baseline deficit in type I IFN production in MF that is restored by psoralen plus UVA therapy and correlates with enhanced antitumor responses. This may explain why MF generally develops in sun-protected skin and suggests that drugs that increase epithelial type I IFNs, including topical MEK and EGFR inhibitors, may be effective therapies for MF.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25000353
- 003
- CZ-PrNML
- 005
- 20250107151820.0
- 007
- ta
- 008
- 250107s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jid.2023.06.212 $2 doi
- 035 __
- $a (PubMed)37716650
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Yu, Zizi $u Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 245 10
- $a Phototherapy Restores Deficient Type I IFN Production and Enhances Antitumor Responses in Mycosis Fungoides / $c Z. Yu, P. Vieyra-Garcia, T. Benezeder, JD. Crouch, IR. Kim, JT. O'Malley, PM. Devlin, A. Gehad, Q. Zhan, JE. Gudjonsson, MK. Sarkar, JM. Kahlenberg, N. Gerard, JE. Teague, TS. Kupper, NR. LeBoeuf, C. Larocca, M. Tawa, B. Pomahac, SG. Talbot, DP. Orgill, P. Wolf, RA. Clark
- 520 9_
- $a Transcriptional profiling demonstrated markedly reduced type I IFN gene expression in untreated mycosis fungoides (MF) skin lesions compared with that in healthy skin. Type I IFN expression in MF correlated with antigen-presenting cell-associated IRF5 before psoralen plus UVA therapy and epithelial ULBP2 after therapy, suggesting an enhancement of epithelial type I IFN. Immunostains confirmed reduced baseline type I IFN production in MF and increased levels after psoralen plus UVA treatment in responding patients. Effective tumor clearance was associated with increased type I IFN expression, enhanced recruitment of CD8+ T cells into skin lesions, and expression of genes associated with antigen-specific T-cell activation. IFNk, a keratinocyte-derived inducer of type I IFNs, was increased by psoralen plus UVA therapy and expression correlated with upregulation of other type I IFNs. In vitro, deletion of keratinocyte IFNk decreased baseline and UVA-induced expression of type I IFN and IFN response genes. In summary, we find a baseline deficit in type I IFN production in MF that is restored by psoralen plus UVA therapy and correlates with enhanced antitumor responses. This may explain why MF generally develops in sun-protected skin and suggests that drugs that increase epithelial type I IFNs, including topical MEK and EGFR inhibitors, may be effective therapies for MF.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory kůže $x terapie $x farmakoterapie $7 D012878
- 650 _2
- $a CD8-pozitivní T-lymfocyty $x patologie $7 D018414
- 650 12
- $a mycosis fungoides $x terapie $x farmakoterapie $7 D009182
- 650 _2
- $a fototerapie $7 D010789
- 650 _2
- $a exprese genu $7 D015870
- 650 12
- $a furokumariny $x terapeutické užití $7 D011564
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vieyra-Garcia, Pablo $u Research Unit for Photodermatology, Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
- 700 1_
- $a Benezeder, Theresa $u Research Unit for Photodermatology, Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
- 700 1_
- $a Crouch, Jack D $u Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 700 1_
- $a Kim, Ira R $u Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 700 1_
- $a O'Malley, John T $u Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 700 1_
- $a Devlin, Phillip M $u Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
- 700 1_
- $a Gehad, Ahmed $u Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 700 1_
- $a Zhan, Qian $u Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 700 1_
- $a Gudjonsson, Johann E $u Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA
- 700 1_
- $a Sarkar, Mrinal K $u Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA
- 700 1_
- $a Kahlenberg, J Michelle $u Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
- 700 1_
- $a Gerard, Nega $u Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 700 1_
- $a Teague, Jessica E $u Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 700 1_
- $a Kupper, Thomas S $u Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Center for Cutaneous Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
- 700 1_
- $a LeBoeuf, Nicole R $u Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Center for Cutaneous Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
- 700 1_
- $a Larocca, Cecilia $u Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Center for Cutaneous Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
- 700 1_
- $a Tawa, Marianne $u Center for Cutaneous Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
- 700 1_
- $a Pomahač, Bohdan, $u Division of Plastic and Reconstructive Surgery, Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA $d 1971- $7 xx0117402
- 700 1_
- $a Talbot, Simon G $u Division of Plastic and Reconstructive Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 700 1_
- $a Orgill, Dennis P $u Division of Plastic and Reconstructive Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 700 1_
- $a Wolf, Peter $u Research Unit for Photodermatology, Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria. Electronic address: peter.wolf@medunigraz.at
- 700 1_
- $a Clark, Rachael A $u Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: rclark@bwh.harvard.edu
- 773 0_
- $w MED00002756 $t Journal of investigative dermatology $x 1523-1747 $g Roč. 144, č. 3 (2024), s. 621-632.e1
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37716650 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250107 $b ABA008
- 991 __
- $a 20250107151817 $b ABA008
- 999 __
- $a ok $b bmc $g 2245132 $s 1236353
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 144 $c 3 $d 621-632.e1 $e 20230915 $i 1523-1747 $m Journal of investigative dermatology $n J Invest Dermatol $x MED00002756
- GRA __
- $a P30 AR069625 $p NIAMS NIH HHS $2 United States
- GRA __
- $a T32 AR007098 $p NIAMS NIH HHS $2 United States
- GRA __
- $a P30 AR075043 $p NIAMS NIH HHS $2 United States
- GRA __
- $a R01 AR065807 $p NIAMS NIH HHS $2 United States
- GRA __
- $a U01 CA253190 $p NCI NIH HHS $2 United States
- GRA __
- $a R01 CA203721 $p NCI NIH HHS $2 United States
- GRA __
- $a R01 AR074797 $p NIAMS NIH HHS $2 United States
- LZP __
- $a Pubmed-20250107
